Biodesix, Inc. reported a total revenue of $21.8 million for the third quarter of 2025, marking a 20% increase compared to $18.2 million in the same period last year. The growth was driven by a 16% rise in lung diagnostic testing revenue, which reached $19.8 million, attributed to an increase in tests delivered and improvements in average revenue per test. Additionally, the company saw a significant 97% increase in Development Services revenue, totaling $1.9 million, as a result of fulfilling existing contracts and securing new agreements.
The company's operating expenses for the third quarter were $28.8 million, an increase of 8% from $26.7 million in the prior year. This rise was primarily due to increased sales and marketing costs associated with expanding the sales team to support growth in lung diagnostics. Notably, the company reported a net loss of $8.7 million for the quarter, which represents a 15% improvement from the $10.3 million loss recorded in the same quarter of 2024. The gross margin improved to 81%, up from 77% in the previous year, reflecting better cost management and increased efficiency in testing workflows.
In terms of financial position, Biodesix had cash and cash equivalents of $16.6 million as of September 30, 2025, a decrease from $26.2 million at the end of the previous fiscal year. The decline in cash was influenced by a $5.2 million increase in accounts receivable, reflecting higher revenue from lung diagnostic testing and new Development Services agreements. The company also raised approximately $4.8 million through its at-the-market offering during the quarter, which partially offset cash outflows.
Strategically, Biodesix has been focusing on expanding its product offerings and enhancing its market presence. The company has invested in clinical studies to support the utility of its tests, including the ongoing INSIGHT study, which aims to validate the predictive and prognostic value of its VeriStrat test. Furthermore, the company has entered into new agreements with biopharmaceutical partners to enhance its Development Services, which are expected to contribute to future revenue growth.
Looking ahead, Biodesix anticipates continued growth in both its diagnostic testing and Development Services segments. The company is committed to increasing its sales and marketing efforts to drive product adoption and expand its customer base. However, it remains cautious about potential challenges related to reimbursement from third-party payers and the need for ongoing investment in research and development to maintain its competitive edge in the diagnostic solutions market.
About BIODESIX INC
Biodesix, Inc. develops and commercializes blood-based diagnostic tests focused on lung disease, including lung cancer diagnosis, treatment guidance, and monitoring. Its core products combine proteomics, genomics, and AI technologies to provide personalized, timely clinical insights for healthcare providers and biopharmaceutical partners. Biodesix operates CLIA-certified labs in the U.S., serving pulmonologists, hospitals, and research institutions with proprietary tests that improve patient outcomes and reduce unnecessary procedures.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.